Skip to main content
CBIO logo

CBIO · Crescent Biopharma, Inc. · Documents

Track CBIO — free
$13.00 +0.09 (+0.70%) At close · Nov 20
Market Cap
$505.64M
Shares
38.90M
Volume · Nov 20 422.38K Avg daily vol (3M) 358.97K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $10.84M 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $3.12M 10-Q filed Nov 12, 2026 Latest results CR-001 dose escalation completed; cash runway extends into 2028 8-K filed Nov 12, 2026
2026
Nov 18
Investor event
Nine INDs cleared with Colune; Phase III planned early 2028

Crescent Biopharma said it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year. It plans to start the first of multiple Phase III studies in early 2028.

3 source passages
We have cleared nine INDs between ourselves and Colune Biotech, our partner, over the course of this year, by the middle of next year, we'll have over 2,000 patients dozed across the entire portfolio. We put out a press release set by early 2028, where I'll start the first of our multiple phase three studies. Open the document at this passage
Nov 18
Investor event
Three programs dosing; nine INDs cleared with Colune Biotech

Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028.

4 source passages
We have three programs we brought into clinic this year, all now dosing patients, and we can talk more about some of the milestones associated with those. We have cleared nine INDs between ourselves and Colune Biotech, our partner, over the course of this year, And we really are executing on our global strategy to deliver on combination therapies for patients that are living with oncology. And, you know, like we said, by the middle of next year, we'll have over 2,000 patients dozed across the entire portfolio. We put out a press release set by early 2028, where I'll start the first of our multiple phase three studies. Open the document at this passage
Nov 12
Current report 8-K
CR-001 dose escalation completed; cash runway extends into 2028

Crescent Biopharma completed Phase 1/2 ASCEND dose escalation after dosing more than 125 patients and plans initial CR-001 monotherapy data in Q1 2027. Cash was $289.4 million as of September 30, 2026, funding operations into the second half of 2028.

Financial results
3 source passages
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027 Cash and cash equivalents were $289.4 million as of September 30, 2026 which includes the $133.4 million in net proceeds from the July 2026 public offering. Crescent expects that its existing cash and cash equivalents will fund operations into the second half of 2028. Waltham, Mass., November 12, 2026 – Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2026 and recent business highlights. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
APOLLO launched; nine-month loss reaches $85.8 million

Crescent Biopharma, Inc. initiated the global Phase 1/2 APOLLO trial in the fourth quarter of 2026 and reported a nine-month net loss of $85.8 million. Cash was $289.4 million as of September 30, 2026.

Revenue $3.12M Net loss $37.73M
Read from the MD&A section
4 source passages
As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” “the Company,” “Crescent Biopharma, Inc.,” “Crescent,” “GlycoMimetics, Inc.,” “GlycoMimetics,” refers to Crescent Biopharma, Inc. and its consolidated subsidiaries, including Crescent Biopharma Operating Company LLC, taken as a whole. In October 2026, CR-002 received allowance to proceed under an Investigational New Drug Application (“IND”) from the FDA, and we initiated the global Phase 1/2 APOLLO trial in the fourth quarter of 2026 in patients with advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, and various gastrointestinal and gynecological tumors. We incurred a net loss of $37.7 million and $85.8 million for the three and nine months ended September 30, 2026. As of September 30, 2026, we had cash and cash equivalents of $289.4 million. Open the document at this passage
Nov 10
Investor event
CR001 data planned for Q1-2027

Crescent Bio plans Q1-2027 safety and tolerability data from 125-plus CR001 monotherapy patients, plus ORR results for up to 12 frontline non-small cell lung cancer patients against a 50 percent benchmark.

5 source passages
Crescent Bio, we have Josh Brown, the CEO. So we have released a press release on our progress a couple of weeks ago that we have dosed more than 125 patients of monotherapy CR001 in the study. So with regards to the data package that we are working on to release in Q1-2027, includes safety tolerability coming from 125-plus patients of various tumor types and per-dose level. In terms of anti-tumor activity that you were alluding to, we will be focusing on up to 12 patients of frontline non-small cell lung cancer patients. And so our benchmark will be 50 percent, again, coming from Harmony2 study. Open the document at this passage
Nov 9
Investor event
CR001 data precedes phase three plans

Crescent plans Q1-2027 CR001 monotherapy data and a first phase three study in early 2028.

3 source passages
the synergistic combination strategy that Crescent was founded to execute upon. So, the clinical data that we are presenting in Q1-2027 is focusing on monotherapy CR001. our first phase three study in early 2028 as well. Open the document at this passage
Oct 15
Current report 8-K
Other events

Crescent Biopharma began ASCEND chemotherapy-combination enrollment, plans additional ADC combination studies, received IND allowance for CR-002, and expects APOLLO initiation in the fourth quarter of 2026 and initial data in the second half of 2027.

Jul 15
Current report 8-K Events of Jul 14
Other events AI summary on its way
Apr 21
Proxy statement DEF 14A Meeting Jun 2, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $10.84M Net loss $153.94M
2025
2024
Showing 1–50 of 121 documents
Key facts CIK 1253689 CUSIP G2545C104 13F (30d) 102 filings 99 filers Visit website Investor relations